SV

ReviewIncont Pelvic Floor Dysfunct 2012; 6(3):69-73

�� !"#$%�� &'(C�� !"#$%&'()*+,

��

�� !"# �� !

�� !"#$%&'()*+,-./0/12321�� !"#$%&'(� �� !" E-mail: chungshiudong@gmail.com

�� !"#$%&'()�*+,-./0E1F�� !"

�� !"#$%E2F�� !"��#$% !&��'()*

�� !"E3F�� !"#C�� !"#$%&'()*+,

�� !"#$E4F�� !"

�� !"#�$%&'(

�� !"#$%&� !"'(Echronic prostatitisF��

�� !"#$%&'�()!*+,-./01234567

�� !"#$%&'(%)*+,-./0123*4567

�� !"#$2008�� !"#$%&'()*+,-./0

�� !"#$%&'()*+,-./5α�� E5α-reductase

inhibitor, 5ARIF�� !"#$%&'()*+,-+./0 1

�� !"# 8,224�� !x1z�� !"#$%&'( 9 ��

�� !"#$%&'()*+,��-./015.4%�� !

�� !"#$%77.6%�� !"#$%&'21.6%�� !

�� !"#$%&'(�� !)*+,-./97.9%��

�� 1.9%�� !"#$%0.2%�� !"#$%&'()

�� !"#$%&'!()89%�� !"#10.7%�� !

��0.3%�� !"#$%&'()*+,-./012345

�� !"#$%&'()*+,"-."#$%/01234

�� !"#$%&%'()*+,#-./01 23456

�� !"#$%&'()*+,-./

�� !"#$%&'()*+,%-./'0123*4

�� !"#$%&'()*+,-./E�� !"#$%&

International Prostate Symptom Score, IPSSF�� !"#$%&'

IPSS�� ! IPSS�� !"#$%&'"#$()*"#

�� !"#�$%&'()*+,-./0)12345�6

�� !"#$%&'()*+,-./0123456789

�� !"#$%&'()IPSS�� !"#$%&'()'*

�� !"E� 1F�

�� !"#$%&'()*+,-./0123IPSS��

�� !"#$%&'()*+�,-./012345�67

�� !"#$%&'()*+*,-./012345�67

�� !"#$IPSS�� !"#$%&'()*+,-./0

�� !"#$%&'()*+,Ebody mass index, BMIF��

�� !"#!$%&'()*+',-./0123456"

�� !"#$%&'()*+,-./012IPSS�� !"

�� !"#$%&'()*+,-./0123456#78

�� !"#$%&'()*!+,-./01�23!+,4

�� !"#$%&'()

�� !"#$%&'()*+!"#$,-$./012

�� !"#Kramer�� !"#$%&'()*+,-�./

�� !"#EcytokinesF�� !"Egrowth factorsF�� !"#

�� !"#$%&'()*+(,-./0%12x2z�� !

�� !"#$%&'()*+,-./0123456-7/

�� !"#$%&'()*+��,-./"0123456

�� !"#$%&'()&*( +,-./0123+,(

�� !"#$%&�'()*+,-./012345678

�� !"#$%&'()*+,-./0!12)34567

� 1K �� !"#$%&'()*+,-./012345678%9:;<=>?� !"#$%&'()@*+,-./IPSS��� !"#$%&'(&)*+',-x1z

Average acute inflammation Average chronic inflammation

N Correlation coefficient P-value N Correlation coefficient P-value

Total IPSS score 8151 -0.001 0.91 8151 0.057 < 0.0001Grouped IPSS score 8151 -0.002 0.84 8151 0.053 < 0.0001Irritative subscore 8037 0.002 0.84 8037 0.056 < 0.0001Obstructive subscore 8014 -0.009 0.42 8014 0.046 < 0.0001Nocturia subscore 8109 -0.002 0.87 8109 0.040 0.0003

IPSS=International Prostate Symptom Score

��

TM

Review

�� !"#$%&'()*+,-./01234%5678

�� !"#$%&'(x3z�

� Kramer�� !"#$%&'()*+,-./�01

�� !"#$%&'()*+,-.�/0)123456'

�� !"#$%&&'()*+,E�1F�� !"#$T��

�� !"#$%&'()*+,- !"(.$/T�� !

�� IL-17 � IFN-g � IL-2 � IL-4 � IL-13 � FGF-2�� !

�� !"#$%&'( IL-6� IL-8� IL-15�� !"#$%

�� !"#$%&'()*�+,#-./-(0�1234

�� !"#$%&'()*+,-#./01234 56%

��x2z�

�� !"��#$% !&��'()*+,-.

�� !"#$%&'()*&'+,-./012Echronic

pelvic pain syndrome, CPPSF�� !"#$%&'()*+,�

�� !"#$%&'()*+,-./01234IL-8��

�� !"#$%Efibroblast growth factor 2, FGF-2F�� !"#

�� !"#$%&'()*++,-./0123�456IL-

10�� !"#$%&'()*+,- ./012234+5

�� !"#$%&'()*+,-./0123*45#$'

�� !"#$E� 2Fx4z�

�� !"#$%&'()*+,-./0123456,

�� !"#$%&'()*+,-./012�3#4567

�� !"#$%&'()*+,-./0123456789

�� !"#$�%&'()*+,-�./01234567

�� !"#$%&'()*+,-./0&1(234567

�� !"#$$%&x5z�

� 1K �� !"#$%&'()*+,&-./0123456789:+;<5=>?(@A3BCDEF6�� 0GH(I�x2z�

Primary Injury

Time

Degree ofprostaticgrowth

Chronicinflammation

Exaggerated/MisdirectedImmune/Autoimmune pesponse

InfectionForeign antigen

Cellular injury Exposure to autoantigen Change in hormonal milieu

Trauma(Duct rupture due to obstruction)

� 2K �� !"#$%!"&'()*+,-Echronic pelvicpain syndrome, CPPSF�� !"#$%&'()*�+,�� !"#$%&'()*+,-./012IL-8���� !"#$%&Efibroblast growth factor 2, FGF-2F���� !"#$x4z�

Stroma

Lumen

Tissue damage

� Cytokine

PAIN � IL8

� WBC

FGF2growth factors

Genetic predisposition low systemic IL-10 NOXA

Fibromuscular tissue growth

�� !"#$%&'()*+,-./012+,345

�� !"#$%&'()*%+,-./01'234567

�� !"#$%&'()*+,� -./0123456

IFN-γ� IL-6 � IL-8�� !"#$%&'()*+� IL-10 �

�� !"#$"%&'()*+,-./0&'(12)34

�� !"#$%&'()'*+,-./0123"4567

�� !"#$%&'()*+,$-./01234E�3Fx6z�

�� !"#`�� !"#$%&'()*+,-./

��

�� !"#$%&'()*+,-.!"/01234

�� !"#$%&'()*+,-.�/01234)567

�� !"#$%&'()*+,-./0123'45678

TN

Review

�� !"#$%&'(NHANES III�� !"C�� !EC-

reactive protein, CRPF�� !"#$%&'()*+,-./0

�� !"#$%&x7z�� !"#$%&'()*+,-$.

�� !"#$%&C�� !"#$%&'()*+,-&.

�� !"#$% 0.32 mg/dL�� !" 3� 4�� !"#$

�� !"#0.35 mg/dLEp=0.06F�� !"#$%&'()*(

�� !"#$%&'C�� !"#$ 0.36 mg/dLEp=0.06F�

�� !"#$%&'()*+,-./01234567

�� !"#$%&'()*+,-./0123'4,%+,

�� !"#$%&'()*+,-./0x8z�� !"#$%

�� !"#$�%&'()*+,'-./01"23456

�� !"#$%&'()*+,-'./0"12,34C�

�� !"#$%&'(&)*+,-./012345678

�� !"#$ %&x9z�� !"#$%&'()*+,-

�� !"#$%&'(C�� !"#$%&'()*+,-

�� !"#$%&'()*+,-"./0123456%7

�� !"#$%&'()*+,-./012�34�567

�� !"#$%�&'()*+,-$./0

�� !"#$ %&'(�)*+,-./012,-.

�� Interleukin-8�� !"#$%&'()*+,-./0)

�� !"#$%&�� '( IL-8�� !"#$x10z��

IL-8�� !"#$%&'()*$%&'(+,-./$%&

� 3K �� !"#$%&'()*+,-./012+,3456789:;<=>?@ABCDE FGH%IJKLMNBCO�� !"#$%&'()*+,-./012 IFN-γ� IL-6 � IL-8�� !"#$%&'()*+� IL-10 ��x6z�

Endocrine�Altered androgen receptors

Immune response� Imbalance of cytokines

� Proinflammatory: IFN-γ, IL-6, IL-8 (IL-10, TNF-α, IL-1β)� Anti-inflammatory: IL-10

� Autoimmune process

Nervous system�Neurogenic inflammation with NGF� Low local levels of β-endorphin

Psychological factors�Stress�Anxiety/Depression

Reduced stress lowers IL-6, IL-10 levels Stress induced mast cell degranulation

Testosterone inhibits effects of NGFLocal inflammation:Inhibits testosterone synthesis

Low testosterone:�� Local inflamation�Autoimmune response

Mechanisms in Prostatitis/Chronic Pelvic Pain Syndrome

�� !"#$%&'()*+,-./012345678

�� !"#$IL-8�� !"#$%&'()*+,-./"

x11z�� !"#$%&'()*+ IL-8�� !"#$%&'

IL-8�� !"#$%&'()*+,-./01+,2345

�� !"#$%&'()*+,-./0"12345678

��

�� !"#$%&'()*+,-./0123,-./

�� !"#$%&'()*+,-./0123456789

�� !"#$%&'()*+,-./0123456789

�� !"#$%&'() Silverio�� ! Refecoxib=ECOX-2

�� !"#$%F�� 5� Finasteride�� !"#$%

�� !"#$%&'()"*+x12z�� !"#$COX-2�

�� Finasteride�� !"#$ Finasteride�� !" 4 ��

�� !"#$%&�'()*+COX-2�� !Finasteride�

�� !"#$%&'()*+,-./01�2Finasteride�

�� !"#$%&'()*+,-./01

�� !"#$%&'()COX-2�� !"#$%&'(

�� EDoxazosinF�� !"#$%&'(x13z�� !"#$

�� !"#$%COX-2�� !"#$%&'�� ()*+

�� !"#$%&'()*+,-./012345Eoveractive

bladder symptom score, OABSSF�IPSS�� !IPSS�� !"

�� !"#$%&'()�*+,-./012345678

��

TO

Review

�� !"#$%&'()*+,-./01234567

�� !"#$%&'()*+,-.$/0.12)*+34

�� !"#$%x14z�� !"#$%&'()*+,-./

�� !"#$%&'(ENSAIDF�� !"#$%&'NSAID

�� !"#$%&'()%�*+,-./01�23+4

�� !"#$%&=> 30 mL�� !"#$%&'()=> 1.4

ng/mL�� !"#$%&'(�)*+,-.�/01�23

�� !"#$%&'()*+,-./0123456789

�� !"#$%&'()*"+,-./012345.60

�� !"#$%&'

�� !"#$%�� &'()*+,-�� ./01

�� !"#$%&'()*+",-./012345678

�� !"#$%&'()*+��,- !"./0123

�� !"#$%&'()*+,-./"012*34"5

�� !"#$%&'()*+,-%./0123"45%6

�� !"#$%&'$%()*+#,-./01&()23

�� !x15z�� !"#$%&'()*+,-./01&*

�� !"#$%&'()*+,-./01234567.8

�� !"#$%&'()*+,-./01#$-2%&'3

�� !"#$%&'()!*+,-./(01234!*

�� !"#$%&'()*'+,"-�./(0123'4

��

�� !"#$%&'()*+,-./01234567

�� !"#$%&'()*+,-./0123� !"#$

�� !"#$%&'!%()*+,-./012010�3��

12�� !"#$ 40�� !"#$%&'()*+,-.-

�� !"#$%&'()*+,-./0!1234 +,-

�� !"#$% !"&'()*+,-./0123*+

�� !"#$%&'()*+, !-.!Epost-void residual,

PVRF�� !"#$%&'()*+,-./0Doxazosin 4 mg

�Tolterodine 4 mg��12�� !21�� !"#$%&'102

�� !"#$%&'()�*+, !"#$(-./*01

�� !"#$%&'()*+,-./0123456789

�� !"#$%&"#$'()�*+,-./012345

�� !"#$%&'()*+,-./0 123#45/)

�� !"#$%&'()*+,-./012(345678

�� !"#$%&'()*+,-

�� !"#$%&'()*+,21�� !"#$%&'

�� !"#$%�&'()$*+,-."/0123"#$

�� !"#$%&'()*+,-./0!"#1&23,4

E�2F�� !"#$%&'()*!+,-./0(%12()

�� !"#$%&'()*+,-./�012345678

�� !"#$%&'()*�+,-./0"#$12345

�� !"#$% &'()*+,-./012345678

�� !"#$%&'()"#*+,$(-./012345

�� !"#$%&'()*+,-./01234,5678

�� !"#$%&'()*+,-./0123456789

�� !"#$%&'()*+,#-./ 012345#6

�� !"#$%&'()*+,$-./012345

�� !"#$%&'()*+,-./0123"456

�� !"#$%&'()*+,-./0123456789

�� !"#$%& '()*+,-./01 234567

�� !"#$%&'()*+,-./0123!/014

�� !"#$%&'()*+,-�./01 23456)

�� !"#$%&'()*+,-./0)*+1/2(34

�� !"#$%&'()*+,-./0"1234%567

�� !"#$%!&'()*+,-.'!/0+123$%

�� !"#$%&'()*+,

�� !

�� !"#$%&�'()*+,-./012+345

� 2K �� !"#$%&'(")*+,-./01234&'(5*6708

Non-calculi (N=21) Calculi (N=102) PAIR (N=21)

Mean (±SD)P-value

Mean (±SD)P-value

P-value

Before After Before After Before After

IPSS 16.8±8.23 5.1±6.34 0.000 18.4±7.8 7.4±8.6 0.000 0.940 0.002TPV 32.8±14.1 35.2±20.4 0.592 40.1±22.4 37.4±21.9 0.053 0.941 0.677PSA 2.1±1.9 2.7±2.9 0.183 6.2±2.5 2.1±2.3 0.020 0.417 0.551Volume 286.2±183.9 367.3±191.4 0.023 225.3±144.8 253.3±167.7 0.085 0.613 0.019Qmax 12.4±5.1 14.6±3.2 0.065 12.6±7.5 14.6±7.4 0.022 0.381 0.837PVR 41.6±28.6 91.0±72.7 0.570 80.2±104.8 64.2±99.4 0.180 0.255 0.028

IPSS= International Prostate Symptom Score; TPV= total prostatic volume; PSA= prostatic specific antigen; Qmax= maximum flow rate; PVR=post-void residual

TP

Review

�� !"#$%&'()*+,-./0123&45678

�� !"#$%&'()*+,%-./012345678

�� !"#$%&'()*+,-./012()*+345

�� !"#$%&'()*+,-./01'2345*67

�� !"#$%&'()*+,-./01234567C�

�� !"#$%&'()*+,-./&'0123456/

�� !"#$%&'()*+,-./0123456789

�� !"C�� !"#$%&'()C�� !"#$%&

�� !C�� !"#$%&'()*+

�� !"#$%&'()*+,-#./01%&'(5α

�� �� !"#$%&'()*+,-./012345�

�� !"#C�� !"#$%&'()*+,-./C��

�� !"#$%&'() *+,-./01234567-

�� !C�� !"#$%&'()*+,-./01234

�� !"#$%& !"#'%()��*+,C�� !"

�� !"#$%&'�()*+,-"./012345�6

�� !

�� !

1. Nickel JC, Roehrborn CG, O'Leary MP, Bostwick DG, SomervilleMC, Rittmaster RS: The relationship between prostate inflamma-tion and lower urinary tract symptoms: Examination of baseline datafrom the REDUCE trial. Eur Urol 2008; 54:1379-1384.

2. Kramer G, Mitteregger D, Marberger M: Is benign prostatic hyper-plasia (BPH) an immune inflammatory disease? Eur Urol 2007; 51:1202-1216.

3. De Marzo AM, Platz EA, Sutcliffe S, et al: Inflammation in prostatecarcinogenesis. Nat Rev Cancer 2007; 7:256-269.

4. Dellabella M, Milanese G, Sigala S, et al: The role of the prostaticstroma in chronic prostatitis/chronic pelvic pain syndrome. InflammRes 2009; 58:829-836.

5. Rudick CN, Berry RE, Johnson JR, et al: Uropathogenic Escheri-chia coli induces chronic pelvic pain. Infect Immun 2011; 79:628-635.

6. Pontari MA, Ruggieri MR: Mechanisms in prostatitis/chronic pelvicpain syndrome. J Urol 2008; 179(5 Suppl):S61-S67.

7. Rohrmann S, De Marzo AM, Smit E, Giovannucci E, Platz EA: Se-rum C-reactive protein concentration and lower urinary tract symp-toms in older men in the Third National Health and Nutrition Exami-nation Survey (NHANES III). Prostate 2005; 62:27-33.

8. St Sauver JL, Sarma AV, Jacobson DJ, et al: Associations betweenC-reactive protein and benign prostatic hyperplasia/lower urinarytract symptom outcomes in a population-based cohort. Am JEpidemiol 2009; 169:1281-1290.

9. Liao CH, Chung SD, Kuo HC: Serum C-reactive protein levels areassociated with residual urgency symptoms in patients with benignprostatic hyperplasia after medical treatment. Urology 2011; 78:1373-1378.

10. Liu L, Li Q, Han P, et al: Evaluation of interleukin-8 in expressedprostatic secretion as a reliable biomarker of inflammation in be-nign prostatic hyperplasia. Urology 2009; 74:340-344.

11. Penna G, Mondaini N, Amuchastegui S, et al: Seminal plasmacytokines and chemokines in prostate inflammation: Interleukin 8as a predictive biomarker in chronic prostatitis/chronic pelvic painsyndrome and benign prostatic hyperplasia. Eur Urol 2007; 51:524-533.

12. Di Silverio F, Bosman C, Salvatori M, et al: Combination therapywith rofecoxib and finasteride in the treatment of men with lowerurinary tract symptoms (LUTS) and benign prostatic hyperplasia(BPH). Eur Urol 2005; 47:72-79.

13. Ozdemir I, Bozkurt O, Demir O, Aslan G, Esen AA: Combinationtherapy with doxazosin and tenoxicam for the management of lowerurinary tract symptoms. Urology 2009; 74:431-435.

14. St Sauver JL, Jacobson DJ, McGree ME, Lieber MM, Jacobsen SJ:Protective association between nonsteroidal antiinflammatory druguse and measures of benign prostatic hyperplasia. Am J Epidemiol2006; 164:760-768.

15. Kim WB, Doo SW, Yang WJ, Song YS: Influence of prostatic calculion lower urinary tract symptoms in middle-aged men. Urology 2011;78:447-449.

��